Terms: = Lymphoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
103 results:
1. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell lymphoma, Not Otherwise Specified.
Qiu L; Lin P; Khanlari M; Xu J; Cohen EN; Garces S; Miranda RN; Wang W; Fang H; Bueso-Ramos CE; Medeiros LJ; Li S
Mod Pathol; 2023 Dec; 36(12):100349. PubMed ID: 37820764
[TBL] [Abstract] [Full Text] [Related]
2. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome of Mantle Cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
[TBL] [Abstract] [Full Text] [Related]
4. Bendamustine Plus Rituximab for Mantle Cell lymphoma: A Korean, Multicenter Retrospective Analysis.
Yi JH; Kim SJ; Lee JO; Lee GW; Kwak JY; Eom HS; Jo JC; Choi YS; Oh SY; Kim WS
Anticancer Res; 2022 Dec; 42(12):6083-6089. PubMed ID: 36456154
[TBL] [Abstract] [Full Text] [Related]
5. Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
Wang Y; Wang T; Yu Y; Wang Q; Yan Y; Li R; Sun Q; Xiong W; Lyu R; Yu Z; Liu W; Sui W; Huang W; Wang H; Li C; Wang J; Zou D; An G; Wang J; Qiu L; Yi S
Ann Hematol; 2022 Jun; 101(6):1201-1210. PubMed ID: 35437610
[TBL] [Abstract] [Full Text] [Related]
6. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
Mukherjee A; Milton DR; Jabbour EJ; Gulbis AM; Kadia T; Jain N; Ledesma C; Burger J; Ferrajoli A; Wierda W; Medeiros LJ; Kantarjian H; Champlin R; Khouri IF
Leuk Lymphoma; 2022 Apr; 63(4):885-893. PubMed ID: 35225133
[TBL] [Abstract] [Full Text] [Related]
8. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.
Albitar M; Zhang H; Goy A; Xu-Monette ZY; Bhagat G; Visco C; Tzankov A; Fang X; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Young KH
Blood Cancer J; 2022 Feb; 12(2):25. PubMed ID: 35105854
[TBL] [Abstract] [Full Text] [Related]
9. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
You H; Xu-Monette ZY; Wei L; Nunns H; Nagy ML; Bhagat G; Fang X; Zhu F; Visco C; Tzankov A; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Van Krieken JH; Piris MA; Winter JN; Li Y; Au Q; Xu B; Albitar M; Young KH
Oncoimmunology; 2021; 10(1):1928365. PubMed ID: 34350060
[TBL] [Abstract] [Full Text] [Related]
10. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of tp53 mutations on clinical outcome.
Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
[TBL] [Abstract] [Full Text] [Related]
11. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract] [Full Text] [Related]
12. Aggressive B-cell lymphoma with MYC/tp53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract] [Full Text] [Related]
13. What Is Responsible for Heterogeneity in Mantle Cell lymphoma Biology and outcomes?
Witzig TE
Hematol Oncol Clin North Am; 2020 Oct; 34(5):825-835. PubMed ID: 32861280
[TBL] [Abstract] [Full Text] [Related]
14. Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.
Sugita Y; Masuoka J; Kameda K; Takahashi K; Kimura Y; Higaki K; Furuta T; Ohshima K
Brain Tumor Pathol; 2020 Oct; 37(4):127-135. PubMed ID: 32627089
[TBL] [Abstract] [Full Text] [Related]
15. clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
Abrisqueta P; Delgado J; Alcoceba M; Oliveira AC; Loscertales J; Hernández-Rivas JA; Ferrà C; Cordoba R; Yáñez L; Medina A; Motlló C; Iacoboni G; Villacampa G; González M; Bosch F
Br J Haematol; 2020 Sep; 190(6):854-863. PubMed ID: 32519351
[TBL] [Abstract] [Full Text] [Related]
16. B-cell lymphoma 2 family genes show a molecular pattern of spatiotemporal heterogeneity in gynaecologic and breast cancer.
Wang J; Li S; Lin S; Fu S; Qiu L; Ding K; Liang K; Du H
Cell Prolif; 2020 Jun; 53(6):e12826. PubMed ID: 32419250
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with clinical outcomes.
Couëtoux du Tertre M; Marques M; Tremblay L; Bouchard N; Diaconescu R; Blais N; Couture C; Pelsser V; Wang H; Higenell V; Izzi L; Gambaro K; Hoffert C; Srivastava A; Spatz A; Rousseau C; McNamara S; Cohen V; Batist G; Agulnik J
Mol Cancer Ther; 2019 Sep; 18(9):1628-1636. PubMed ID: 31243098
[TBL] [Abstract] [Full Text] [Related]
18. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell lymphomas.
Restelli V; Lupi M; Chilà R; Vagni M; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Damia G; Carrassa L
Mol Cancer Ther; 2019 Jul; 18(7):1255-1264. PubMed ID: 31064869
[TBL] [Abstract] [Full Text] [Related]
19. Lenalidomide for the treatment of mantle cell lymphoma.
Morabito F; Skafi M; Recchia AG; Kashkeesh A; Hindiyeh M; Sabatleen A; Morabito L; Alijanazreh H; Hamamreh Y; Gentile M
Expert Opin Pharmacother; 2019 Apr; 20(5):487-494. PubMed ID: 30608891
[TBL] [Abstract] [Full Text] [Related]
20. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.
Qu X; Li H; Braziel RM; Passerini V; Rimsza LM; Hsi ED; Leonard JP; Smith SM; Kridel R; Press O; Weigert O; LeBlanc M; Friedberg JW; Fang M
Blood; 2019 Jan; 133(1):81-93. PubMed ID: 30446494
[TBL] [Abstract] [Full Text] [Related]
[Next]
